A small, daily dose of aspirin significantly diminishes the risk of death from a wide range of cancers, according to a landmark study.
Long-term use of a daily low-dose aspirin dramatically cuts the risk of dying from a wide array of cancers, a new investigation reveals.
Specifically, a British research team unearthed evidence that a low-dose aspirin (75 milligrams) taken daily for at least five years brings about a 10 percent to 60 percent drop in fatalities depending on the type of cancer.
“These findings provide the first proof in man that aspirin reduces deaths due to several common cancers,” the study team noted in a news release.
But the study’s lead author, Prof. Peter Rothwell, stressed that “these results do not mean that all adults should immediately start taking aspirin.”
“They do demonstrate major new benefits that have not previously been factored into guideline recommendations,” he added, noting that “previous guidelines have rightly cautioned that in healthy middle-aged people, the small risk of bleeding on aspirin partly offsets the benefit from prevention of strokes and heart attacks.”